Pfizer’s fourth-quarter earnings and revenue have topped analyst expectations, driven by stronger-than-expected demand for its COVID products. The company reported adjusted earnings per share of 63 cents, beating the consensus forecast of 46 cents, and revenue of $17.76 billion, exceeding estimates of $17.36 billion.
The COVID-19 treatment pill Paxlovid brought in $727 million in sales, more than doubling the loss recorded last year. The company attributed the growth to strong demand in the US during a recent COVID wave and a one-time contract delivery to the federal government.
In contrast, Pfizer’s COVID shot generated $3.4 billion in revenue, down from $5.4 billion in the same period last year due to lower contracted doses globally. However, this decline was expected by analysts.
Excluding COVID products, Pfizer reported a 12% rise in operational revenue, driven by approved cancer treatments from its acquisition of Seagen for $43 billion. The company also saw growth in sales of its blood thinner Eliquis and certain cardiomyopathy treatments.
Despite beating expectations, shares were down slightly on the news. Pfizer reiterated its full-year 2025 outlook, forecasting sales of $61-64 billion and earnings per share of $2.80-$3. Analysts are watching closely for signs of progress in the company’s long-term financial health and its experimental obesity pill danuglipron.
Source: https://www.cnbc.com/2025/02/04/pfizer-pfe-earnings-q4-2024.html